Strategy overview

To rapidly advance from laboratory experiments to clinical trials in Type 2 Diabetes based on "shortcut" regulatory routes, that enable a shorter time from the lab to treating patients.


Our initial focus is on a leveraging FDA 505(b)(2) designations and Expedited Pathway programs.



Our focus leverages the global demand-creating patient population of about 450 million people with Diabetes.


Our drug for treating Type 2 Diabetes drug (Pill) – extensively demonstrated as effective in both prevention and treatment of T2 Diabetes – by Restoring Insulin Resistance to Normal Levels! Markedly inhibiting the appearance and the degree of hyperglycemia; lowering LDL; lowering body weight; reduction of cataract formation and diabetes-induced retinopathy 


© 2013 - 2020 Concenter BioPharma  Ltd. / Silkim Pharma Ltd.

  • Facebook Clean
  • LinkedIn Clean
  • Twitter Social Icon